[1] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol,2021,18(4):223-238. [2] Jarvis H, Craig D, Barker R, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies[J]. PLoS Med,2020,17(4):e1003100. [3] Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia,1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398. [4] Younossi ZM, Corey KE, Lim JK. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review[J]. Gastroenterology,2021,160(3):912-918. [5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 临床肝胆病杂志,2018,34(5):947-957. [6] Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. J Hepatol,2012,57(1):157-166. [7] Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review[J]. J Hepatol,2017,66(1):142-152. [8] Zelber-Sagi S, Buch A, Yeshua H, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial[J]. World J Gastroenterol,2014,20(15):4382-4392. [9] Furlani IL, da Cruz Nunes E, Canuto GAB, et al. Liquid Chromatography-Mass Spectrometry for Clinical Metabolomics: An Overview[J]. Adv Exp Med Biol,2021,1336:179-213. [10] Yang Y, Huang Z, Yang Z, et al. Serum metabolomic profiling reveals an increase in homocitrulline in Chinese patients with nonalcoholic fatty liver disease: a retrospective study[J]. PeerJ,2021,9: e11346. [11] Tomita K, Teratani T, Yokoyama H, et al. Plasma free myristic acid proportion is a predictor of nonalcoholic steatohepatitis[J]. Dig Dis Sci,2011,56(10):3045-3052. [12] Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis[J]. Hepatology,2011,54(3):837-845. [13] Rom O, Liu Y, Liu Z, et al. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome[J]. Sci Transl Med,2020,12(572):eaaz2841. [14] Gaggini M, Carli F, Rosso C, et al. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance[J]. Hepatology,2018,67(1):145-158. [15] Yamakado M, Tanaka T, Nagao K, et al. Plasma amino acid profile associated with fatty liver disease and co-occurrence of metabolic risk factors[J]. Sci Rep,2017,7(1):14485. [16] 孙亚新. 基于代谢组学技术的二甲双脈对双酚A诱导大鼠肝损伤的保护作用机制研究. 郑州大学,2020. [17] Zouhal H, Jayavel A, Parasuraman K, et al. Effects of Exercise Training on Anabolic and Catabolic Hormones with Advanced Age: A Systematic Review[J]. Sports Med,2022,52(6):1353-1368. [18] Sarkar M, VanWagner LB, Terry JG, et al. Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife.[J]. Am J Gastroenterol,2019,114(5):758-763. [19] Jaruvongvanich V, Sanguankeo A, Riangwiwat T, et al. Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis[J]. Ann Hepatol,2017,16(3):382-394. [20] Dhindsa S, Ghanim H, Batra M, et al. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes[J]. Diabetes Care,2016,39(1):82-91. |